Contact Us
Schwab Client Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.010 -0.010 (-0.98%)
Streaming Delayed Price Updated: 11:56 AM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,927,244
Open 1.025
Bid (Size) 1.010 (25,500)
Ask (Size) 1.020 (12,400)
Prev. Close 1.020
Today's Range 1.000 - 1.040
52wk Range 0.9700 - 2.725
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances ↗
Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive... 
Via MarketBeat

Performance

YTD
-26.8%
-26.8%
1 Month
-23.5%
-23.5%
3 Month
-39.5%
-39.5%
6 Month
-42.3%
-42.3%
1 Year
-30.3%
-30.3%

More News

Read More
News headline image
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming September Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss ↗
Via Chartmill
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗
Via Chartmill
News headline image
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts ↗
Via MarketBeat
News headline image
Ocugen (OCGN) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Retirement
News headline image
Ocugen Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming August Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances ↗
Via MarketBeat
News headline image
Ocugen to Participate in Upcoming July Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming June Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
From Ocugen
Via GlobeNewswire
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Via The Motley Fool
News headline image
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Provides Business Update with First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
From Ocugen
Via GlobeNewswire
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 1.010
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 09/28/26 11:56 AM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 259.90M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 260M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.